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Metabolic syndrome refers to a set of conditions that increases the risk of cardiovascular disease and has been associated with
an increased risk of prostate cancer, particularly among African American men. This study aimed to estimate the association
of metabolic syndrome with biochemical recurrence (BCR) in a racially diverse population. Among 383 radical prostatectomy
patients,67patientshaddocumentedbiochemicalrecurrence.Hypertensionwassigniﬁcantly,positivelyassociatedwiththerateof
BCR (hazard ratio (HR) = 2.1; 95% CI = 1.1,3.8). There were distinct racial diﬀerences in the prevalence of individual metabolic
syndrome components; however, the observed associations with BCR did not diﬀer appreciably by race. We conclude that
hypertensionmaycontributetoapoorerprognosisinsurgicallytreatedprostatecancerpatients.Ourﬁndingssuggestthattargeting
components of the metabolic syndrome which are potentially modiﬁable through lifestyle interventions may be a viable strategy
to reduce risk of BCR in prostate cancer.
1.Introduction
Prostate cancer is the most common invasive cancer diag-
nosed in men and the second leading cause of cancer death
[1].Ofthemenwhoundergoradicalprostatectomyforlocal-
ized prostate cancer, between 17% and 53% will experience
biochemical recurrence (BCR) in the ten years following
surgery [2, 3]. Traditional predictors of recurrence following
radical prostatectomy include preoperative prostate-speciﬁc
antigen (PSA) levels, tumor stage, Gleason’s score, and
surgical margin status [3, 4]. While these predictors are
often used for determining BCR-free survival probabilities
following radical prostatectomy [4], they are nonmodiﬁable
characteristics of disease and as such do not provide patients
with options to positively inﬂuence their disease course.
Given the high level of motivation of most patients in the
early postsurgery follow-up period, modiﬁable targets for
intervention that can increase or permanently delay the time
to BCR would be beneﬁcial [5].
Metabolic syndrome, which is a risk factor for cardio-
vascular disease, refers to a clustering of conditions that
include hypertension, diabetes, abdominal obesity, hyper-
triglyceridemia, and low high-density lipoprotein (HDL)
cholesterol, with insulin resistance as the underlying hall-
mark feature [6]. The metabolic syndrome proﬁle diﬀers
depending upon race, with Caucasians disproportionately
aﬀected with dyslipidemia and African Americans more
likely to be diagnosed with hypertension and diabetes [7, 8].2 Prostate Cancer
Several studies indicate that the metabolic syndrome is
associated with an increased risk of prostate cancer [9–12].
Recent ﬁndings from our own group suggest in fact that race
modiﬁes the association; metabolic syndrome was positively
associatedwithprostatecancerriskamongAfricanAmerican
men, but not among Caucasian men [13].
Metabolic syndrome has an appeal as a predictor of
BCR as its components can be treated and thereby provide
clinicians with a strategy for tertiary prevention. To our
knowledge,theassociationbetweenmetabolicsyndromeand
prostate cancer recurrence has never been systematically
investigated. Therefore, the aims of this study were to
estimate the eﬀects of metabolic syndrome and its individual
components on prostate cancer BCR and to determine if
racial diﬀerences exist with regard to the associations of
interest.
2.MaterialsandMethods
2.1. Study Population and Data Collection. The data for this
investigation were collected as part of a prostate cancer case-
control study conducted at the Henry Ford Health System
(HFHS) in Detroit, Michigan, USA. HFHS provides care to a
racially diverse population in the Detroit Metropolitan area
[14]. Eligibility criteria for participation in the current study
included (1) ≤75 years of age at time of diagnosis, (2) use of
HFHS for the patient’s primary medical care in the 5 years
prior to diagnosis, (3) residence within the study area at
time of recruitment, (4) no serious medical problems that
would prohibit participation, and (5) radical prostatectomy
as the patient’s primary treatment. Cases were diagnosed
with primary adenocarcinoma of the prostate between
January 1, 1999 and December 31, 2004. The diagnosis was
histopathologically conﬁrmed by the HFHS Department of
Pathology. Three hundred-ninety-six (396) prostate cancer
cases were considered eligible for the current investigation
basedontheaforementionedcriteria,withAfricanAmerican
men comprising approximately 40% of the study popula-
tion. All participants completed an interviewer-administered
questionnaire. The questionnaire included information on
sociodemographic characteristics, family history of prostate
cancer, health behaviors including smoking history and
physical activity, occupation, diet, height and weight. Data
extracted from medical records included hypertension, dia-
betes and lipid proﬁles, PSA screening history, pretreatment
PSA levels, clinical and pathological TNM stage, and biopsy
andsurgicalGleason’sscores.Informedconsentwasgathered
from all participants, and the HFHS Institutional Review
Board approved all protocols.
2.2. Metabolic Syndrome Deﬁnition. Metabolic syndrome
wasdeﬁnedusingcriteriaestablishedbytheNationalCholes-
terol Education Program Expert Panel on the Detection,
Evaluation and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III (ATP)) [15]. The ATP
III deﬁnition requires any three of the following ﬁve
components: (1) hypertension (≥130/85mmHg), (2) high
fasting blood glucose (≥110mg/dL), (3) abdominal obesity
(waist circumference >102cm in men), (4) low high-density
lipoprotein (HDL) cholesterol (<40mg/dL), and (5) hyper-
triglyceridemia (≥150mg/dL). In order to accommodate the
available study data, speciﬁc ATP III criteria were modiﬁed.
A body mass index (BMI) of greater than 30kg/m2 was
used as the criterion for abdominal obesity as measures of
waist circumference were unavailable. BMI was calculated
using self-reported height and weight at time of enrollment.
A history of hypertension and/or diabetes prior to their
prostate cancer diagnosis was abstracted from the medical
record and recorded as present or not present.
2.3. Biochemical Recurrence Deﬁnition. Biochemical recur-
rence (BCR) was deﬁned as two consecutive rising detectable
PSA concentrations of >0.2ng/mL [16]. Our criteria for
determining the start of follow-up for identifying men at risk
of BCR required that PSA levels reach a nadir ≤0.2ng/mL
after surgery. PSA levels are typically expected to drop to
near undetectable levels within the four weeks following
radical prostatectomy [17]. To account for the variation in
the timing of PSA testing, only those subjects who reached
≤0.2ng/mL within 6 weeks were included in this analysis.
Thirteen subjects were excluded either because they did not
reach a PSA nadir within 6 weeks, suggesting some residual
disease or lack of PSA follow-up data, making it diﬃcult to
determine when nadir was established.
2.4. Statistical Methods. All statistical analyses were per-
formed using Statistical Analysis Systems software, version
9.2 (Cary, NC, USA). Study population’s demographic
and clinical characteristics were described with appropriate
frequency measures. Patient characteristics included age at
the time of diagnosis, race, and smoking history. Clinical
characteristics included preoperative PSA level, clinical stage
(local, regional, distant), tumor grade, and surgical margin
status. The distribution of metabolic syndrome components
were examined in the total population and stratiﬁed by
race. Diﬀerences in the prevalence of metabolic syndrome
components between the races were evaluated with chi-
square tests.
Crude and adjusted hazard ratios were estimated using
Cox regression. Time to recurrence was modeled as a
function of (1) each individual component adjusted for all
other components and (2) metabolic syndrome (any 3 of 5
features). Multiple models were ﬁt, adjusting for diﬀerent
combinations of patient and clinical characteristics treated
as potential confounders. Age at diagnosis was modeled as
a continuous variable. All other covariates were included in
models as dichotomous variables. Categorization of these
covariates was as follows: a pre-operative PSA level of
>10ng/mL was considered high; a Gleason score 7 (4 + 3)
or greater was designated high grade; regional and distant
stage designations (as determined from clinical TNM and
pathological staging) were categorized as high stage. Models
werefurtherstratiﬁedbyraceandcomparedtotheresultsfor
the total sample.
In addition to the standardized ATP III metabolic syn-
drome deﬁnition examined, previous work has looked at theProstate Cancer 3
Table 1: Frequency distribution (number and percent) of demographic and clinical characteristics among radical prostatectomy patients
(n = 383).
Characteristic All men Recurrence No recurrence
N % N % N %
Age∗ 60.9 10.1 60.6 5.9 60.9 6.8
Race
Caucasian 215 56.1 38 56.7 177 56.0
African American 168 43.9 29 43.3 139 44.0
Smoking history
Ever 249 65.0 51 76.1 198 62.7
Never 134 35.0 16 23.9 118 37.3
Pretreatment PSA (ng/ml)
≤10 331 86.4 50 74.6 281 88.9
>10 52 13.6 17 20.4 35 11.1
Gleason score
≤7 (3+ 4) 280 73.1 41 61.2 239 75.6
≥7 (4+ 3) 103 26.9 26 38.8 77 24.4
Stage
Local 321 83.8 49 73.1 272 86.1
Regional 58 15.2 15 22.4 43 13.6
Distant 4 1.0 3 4.5 1 0.3
Surgical margin status
Positive 111 29.8 38 56.7 73 23.1
Negative 262 70.2 27 43.3 235 76.9
∗Mean value with standard deviation.
Table 2: Frequency distribution (number and percent) of metabolic syndrome features among all participants (n = 383) and by race.
Features All men (n = 383) White men (n = 215) AA men (n = 168)
N % N % N % P value∗
Hypertension 216 56.4 109 50.7 107 63.7 0.01
Diabetes 56 14.6 18 8.4 38 22.6 <0.0001
Obesity 121 31.6 59 27.4 62 36.9 0.05
Low HDL cholesterol 76 22.5 52 26.7 24 16.8 0.03
High triglycerides 141 41.4 93 47.2 48 27.4 0.01
Metabolic syndrome (≥3 features) 95 24.8 49 22.8 46 27.4 0.30
∗Based on Mantel-Haenszel chi-square comparing racial diﬀerences in prevalence of features.
metabolic syndrome as an accumulation of cardiometabolic
abnormalities [18]. With this in mind, the number of
metabolic syndrome components was also evaluated as an
ordinal variable with 3 levels: 0 (referent), 1-2, and 3 or more
components.
3. Results
Patient and clinical characteristics for the 383 patients
included in this analysis as well as the distribution of the
metabolic syndrome and its components are described in
Tables 1 and 2. The mean age at time of diagnosis was
approximately 61 years, and as stated earlier, over 40% of
thepatientpopulationwasAfricanAmerican.Approximately
27% of patients were considered to have high-grade disease
based upon their Gleason’s score with 16% of patients
diagnosed with regionally advanced to distant stage disease.
Hypertension was the most commonly observed meta-
bolic syndrome component with 56% of subjects categorized
as hypertensive. There were appreciable diﬀerences in the
prevalence of each component between Caucasian and
African American patients (Table 2). African Americans had
a higher prevalence of hypertension, obesity, and diabetes
while Caucasians had a higher prevalence of low HDL and
elevatedtriglycerides.However,therewasnodiﬀerenceinthe
prevalence of metabolic syndrome overall by race.
Median follow-up time for patients in the study was 49
months (range 1 to 97 months) with 67 documented recur-
rences (17.5%) during the follow-up period. There was no
diﬀerence between Caucasians (17.7%) and African Amer-
icans (17.3%) in the proportion of patients who recurred.
The adjusted hazard ratios (HR) of BCR by metabolic
syndromecomponentarepresentedinTable 3.Hypertension
was associated with BCR after adjustment for patient and4 Prostate Cancer
Table 3: Adjusted hazard ratios (95% conﬁdence intervals) of biochemical recurrence (BCR) by metabolic syndrome component (n = 383).
Feature % of sample Model 1 Model 2 Model 3 Model 4
Hypertension 56.4 1.9 (1.1–3.3) 1.8 (1.0–3.1) 1.7 (0.99–2.9) 2.1 (1.1–3.8)
Diabetes 14.6 1.0 (0.52–2.1) 0.99 (0.48–2.0) 1.1 (0.52–2.2) 0.99 (0.48–2.1)
Obesity 31.6 1.1 (0.63–1.8) 1.0 (0.59–1.7) 1.0 (0.60–1.8) 0.97 (0.55–1.7)
Low HDL cholesterol 22.5 0.68 (0.36–1.3) 0.57 (0.30–1.1) 0.58 (0.30–1.1) 0.48 (0.24–1.0)
High triglycerides 41.4 0.90 (0.54–1.5) 0.92 (0.54–1.6) 0.92 (0.54–1.6) 1.1 (0.64–1.7)
Metabolic Syndrome
<3 features (referent) 75.2 1.0 1.0 1.0
≥3 features 24.8 1.4 (0.83–2.4) 1.4 (0.85–2.5) 1.5 (0.90–2.6) —
Ordinal Model
0 features (referent) 23.2 1.0 1.0 1.0
1-2 features 52.0 0.96 (0.52–1.8) 0.85 (0.45–1.6) 0.75 (0.39–1.4) —
≥3 features 24.8 1.4 (0.70–2.7) 1.3 (0.65–2.6) 1.3 (0.63–2.5) —
Model 1: adjusted for age and race.
Model 2: adjusted for age, race, and clinical characteristics (pre-operative PSA, Gleason’s grade, tumor stage, surgical margin status).
Model 3: adjusted for age, race, clinical characteristics and smoking.
Model 4: adjusted for age, race, clinical characteristics, smoking, and other metabolic syndrome components.
clinical characteristics and the other metabolic syndrome
features (HR = 2.1 (95% CI = 1.1–3.8). Low HDL level
was inversely associated with the rate of BCR (Model 4:
HR = 0.48; 95% CI = 0.24–1.0). Diabetes, obesity, and
high triglycerides were not associated with BCR among all
patients.
Adjusted hazard ratios for BCR are presented in Table 3
fortwocompositemeasuresofmetabolicsyndrome.Treating
the syndrome as a dichotomous measure (≥3 components
versus <3components),theestimatedhazardratio,adjusting
for age, race, clinical characteristics, and smoking (Model 3),
was 1.5 (95% CI = 0.90–2.6). Treating metabolic syndrome
as an ordinal variable did not reveal any trend of increasing
risk of BCR with increasing number of components.
Whenwestratiﬁedbyrace,wedidnotﬁndanysigniﬁcant
diﬀerencesin theassociation between hypertensionand BCR
(Caucasian: HR = 1.9; 95% CI = 0.90–3.9 and African
American: HR = 2.1; 95% CI = 0.70–6.3; P interaction =
0.91). Race-stratiﬁed estimates of the association between
metabolic syndrome (≥3 components) and BCR suggest a
stronger association among African Americans (HR = 1.6;
95% CI = 0.69–3.8) than Caucasians (HR = 1.2; 95% CI =
0.56–2.5). However, our sample size was inadequate to deter-
mine the signiﬁcance of the diﬀerences in the association (P
interaction = 0.41).
4. Discussion
Ours is the ﬁrst study to examine the association between
the metabolic syndrome and BCR. We observed a 50%
increase in the rate of BCR among patients classiﬁed as
having metabolic syndrome. That ﬁnding was primarily
inﬂuenced by the apparent eﬀect of one metabolic syndrome
component—hypertension, which was associated with an
approximate2-foldincreaseintherateofBCRforbothwhite
and African American men.
Approximately 18% of men had evidence for BCR based
upon our deﬁnition. We found no appreciable diﬀerence in
theBCRratebetweenAfricanAmericanandwhitemen.This
is similar to ﬁndings from two studies that showed race does
n o ta p p e a rt ob ear i s kf a c t o rf o rB C R[ 19, 20].
The positive association between hypertension and BCR
was the only consistent observation among all patients
across all models. Hypertension has been reported to be
associated with prostate cancer risk [10] and more aggressive
tumor characteristics [21]. Furthermore, antihypertensive
medication is associated with a reduced risk of prostate
cancer although this relation has not been examined with
recurrence [22, 23]. Hypertension may promote recurrence
through pathways linked to oxidative stress, whereby reactive
oxygen species and low bioavailability of antioxidants have
been hypothesized to promote prostate cancer cell growth
[24].
Limitations of this analysis are important to consider
for interpretation of the results. The study was designed
to estimate the eﬀects of genetic and environment factors
on the risk of prostate cancer in a case control setting.
Thus, our analysis of biochemical recurrence in a relatively
small subsample of cases has limited statistical power to
detect associations with the metabolic syndrome and its
components, especially when adjusting for several potential
confounders and stratiﬁed by patients’ race. The potential
presence of detection bias cannot be ruled out as men who
have hypertension may be more likely to see a physician
and, therefore, more likely to have PSA follow-up testing.
To address this issue, we examined the frequency of PSA
tests in the two-year period after surgery and found the
mean number of tests between patients with and without
hypertension was nearly identical (4.36 (SD = 1.81) versus
4.37 (SD = 1.93); pooled t-test P = 0.94). Analyses com-
paring postsurgery testing between men with and without
metabolic syndrome (≥3 components) produced similar
results (P = 0.49). Moreover, a previous investigation of the
PSA screening behavior of these patients did not suggest any
diﬀerence in the frequency of PSA testing prior to diagnosis
[13].Prostate Cancer 5
Lipid proﬁles were incomplete for 45 subjects, and this
missing lipid data would likely result in an underestimation
of those subjects classiﬁed as having metabolic syndrome.
Additionally, BMI was calculated based on self-reported
height and weight. Classiﬁcations of abdominal obesity esti-
mated by BMI could be inaccurate. Abdominal obesity is less
common in African American men than other racial groups
[7]. Furthermore, BMI is considered a suboptimal measure
for abdominal obesity, particularly in African American men
because visceral fat is most closely linked with altered lipid
concentrations and insulin resistance [25].
Timing of PSA followup is another limitation of this
analysis. As an observational investigation the PSA followup
was done at the discretion of the treating physician and
limited by subject compliance; the cases were tested for
recurrence at irregular intervals. Similarly, cases with limited
PSA follow-up data were excluded from our analyses. It is
possible, therefore, that undetected BCR events might have
biased the results if PSA followup is more or less likely to
occur based upon the existence of the metabolic syndrome
conditions. It is important to note, however, that there were
few exclusions based upon limited data, and cases with
lengthy intervals (>12 months) between PSA tests were a
small proportion of subjects included.
Among the strengths of this investigation is the reliability
of clinical data for determination of metabolic syndrome
and BCR. Hypertension, diabetes, and lipid proﬁles were
abstracted directly from the medical record. Additionally,
PSA results were available for subjects for a median of 4 years
after diagnosis. Results from prior investigations indicate the
majority of localized prostate cancers that recur after radical
prostatectomy are detected soon after surgery [26]. The
raciallydiverse study population is another major strength of
the investigation as the large percentage of African American
participants makes it ideal to evaluate the inﬂuence of race
on BCR.
5. Conclusions
This investigation was the ﬁrst to evaluate metabolic syn-
drome and its components as predictors of the biochemical
recurrence of prostate cancer after radical prostatectomy
in both African American and Caucasian men. Metabolic
syndrome was modestly, but not signiﬁcantly, associated
with increased BCR, regardless of race. Of the individual
metabolic syndrome components, hypertension was consis-
tently associated with increased BCR. Further investigations
of metabolic syndrome and BCR in larger populations are
needed to replicate these ﬁndings; if validated, the medical
management of hypertension could inﬂuence the long-
term prognosis of men with prostate cancer after deﬁnitive
treatment.
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